Hemophilia B

Pfizer’s Gene Therapy for Rare Bleeding Disorder Gets FDA Approval

Pfizer’s gene therapy for hemophilia B received approval from the U.S. Food and Drug Administration on Friday, April 26, 2024. It is the second such therapy to be approved for the rare bleeding disorder